| Workshop 10 (JSGS・JSGE・JSH) |
| Fri. November 2nd 14:40 - 17:00 Room 2: Kobe International Exhibition Hall No.2 Building Hall South |
Targeting drug metabolic gene expression in gastric cancer
|
|||
| Tovuu Lkhagva-Ochir1, Bayarsaikhan Enkhjargal1 | |||
| 1National Cancer Center of Mongolia | |||
|
|||
|
|||
| Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer, however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of gastric cancer subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define gastric cancer subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, TYMS, TUBB3, STMN, RRM1, hENT1 and TOP2A) and five receptor tyrosine kinesis and demonstrated significant heterogeneity of gene expression among gastric cancer patients. In this study we were analyzed gene expression level among 55 gastric cancer patients who are received surgical treatment at our center. Gene expression levels were analyzed by LC480 II system. TYMS gene is to evaluate the probability of tumor response to fluorouracil-based chemotherapies and its expression level was high in 65% of gastric cancer patients. And 16% of gastric cancer patients express low level of TYMS which indicates less effective to fluorouracil-based chemotherapies. STMN1 and TUBB3 are possible to assess microtubule inhibitors effect those expression were high in 70% of gastric cancer patients. But TOP2A gene expression level were low in 25% of gastric cancer patients. RRM1 and hENT1 gene expression were high in 60% and low in 10% of patients. The results are of immediate translational value regarding gastric cancer diagnostics and therapeutics, as many of these genes are currently widely used in relevant clinical testing. |
|||
|
Index Term 1: gene expression Index Term 2: gastric cancer |
|||
| Page Top | |||